WO2001003666A2 - Compositions pour occlusion vasculaire a base de liquide - Google Patents

Compositions pour occlusion vasculaire a base de liquide Download PDF

Info

Publication number
WO2001003666A2
WO2001003666A2 PCT/US2000/017886 US0017886W WO0103666A2 WO 2001003666 A2 WO2001003666 A2 WO 2001003666A2 US 0017886 W US0017886 W US 0017886W WO 0103666 A2 WO0103666 A2 WO 0103666A2
Authority
WO
WIPO (PCT)
Prior art keywords
precursor composition
biodegradable
biologically active
mass
occlusive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/017886
Other languages
English (en)
Other versions
WO2001003666A3 (fr
Inventor
Robert M. Abrams
Paul C. Slaikeu
James J. Barry
Joseph C. Eder
Michael P. Wallace
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Scientific Scimed Inc
Original Assignee
Scimed Life Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scimed Life Systems Inc filed Critical Scimed Life Systems Inc
Priority to AU60580/00A priority Critical patent/AU6058000A/en
Publication of WO2001003666A2 publication Critical patent/WO2001003666A2/fr
Publication of WO2001003666A3 publication Critical patent/WO2001003666A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/046—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10—Polypeptides; Proteins
    • A61L24/102—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10—Polypeptides; Proteins
    • A61L24/106—Fibrin; Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10—Polypeptides; Proteins
    • A61L24/108—Specific proteins or polypeptides not covered by groups A61L24/102 - A61L24/106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors

Definitions

  • This invention relates to compositions for forming a biologically active anatomical occlusion typically within the vasculature of a patient. More particularly, it concerns an occlusive agent which may be made from a precursor composition containing at least one biodegradable, polymeric component and at least one biologically active agent.
  • the occlusive agent may further include solid or dissolved radio-opacifiers and known vaso- occlusive devices.
  • the resulting occlusion a bioactive solid, encourages cellular attachment and growth while maintaining favorable handling, deployment, and visualization characteristics.
  • This invention relates to liquid-based polymeric compositions, or occludant precursors, that may be injected via a catheter to form occlusions in a selected body region.
  • the resulting bioactive solid materials may be used to block blood flow in portions of malfunctioning human organs such as the kidney, spleen, and liver, or to block blood flow into the malfunctioning areas of blood vessels such as arterio-venous malformations (AVM) and aneurysms.
  • AVM arterio-venous malformations
  • embolization The artificial blocking of blood flow is known generically as "embolization.”
  • embolization The embolization of a vessel in an organ may be used to treat a variety of maladies; typically, though, embolization is used: 1) to control the bleeding caused by trauma, 2) to prevent profuse blood loss during an operation requiring dissection of blood vessels, 3) to obliterate a portion of or a whole organ having a tumor, or 4) to block the blood flow into abnormal blood vessel structures such as AVM's and aneurysms.
  • cyanoacrylate glues have an advantage over other embolic materials in ease of delivery in that they are the only liquid embolics currently available to neurosurgeons.
  • the constituent cyanoacrylate polymers have the disadvantage of being biodegradable. The degradation product, formaldehyde, is highly toxic to the neighboring tissues. See, Vinters et al, "The Histotoxocity of Cyanoacrylate: A Selective Review", Neuroradiology 1985; 27:279-291.
  • Another disadvantage of cyanoacrylate materials is that the polymer will adhere both to the blood vessel and to the tip of the catheter. Thus physicians must retract the catheter immediately after injection of the cyanoacrylate embolic material or risk adhesion of the cyanoacrylate and the catheter to the vessel.
  • Embolization Method Combined Administration of Ethanol-Estrogen and Polyvinyl Acetate", Neuro Med Chir (Tokyo) 1993; 33:71-76; Taki et al, "A New Liquid Material for Embolization of Arterio- Venous Malformations", AJNR 1990:11 :163-168; Mandai et al, "Direct Thrombosis of Aneurysms with Cellulose Acetate Polymer. Part I: Results of Thrombosis in Experimental Aneurysms.” J. Neurosurgery 7992; 77:493-500. These materials employ a different mechanism in forming synthetic emboli than do the cyanoacrylate glues.
  • Cyanoacrylate glues are monomeric and rapidly polymerize upon contact with blood.
  • Precipitative materials are pre-polymerized chains that precipitate into an aggregate upon contact with blood.
  • the polymer is dissolved in a solvent that is miscible with blood, and upon contact with that blood, the solvent is diluted and the water-insoluble polymer precipitates.
  • the precipitate forms a solid mass and thus occludes the vessel.
  • PVAc polyvinyl acetate
  • EVAL poly(ethylene-co-vinyl alcohol)
  • CA cellulose acetate
  • Taki et al "A New Liquid Material for Embolization of Arterovenous Malformations", AJNR 1990; 11 :163-168 and Mandai et al, "Direct Thrombosis of Aneurysms with Cellulose Polymer: Part I: Results of Thrombosis in Experimental
  • vaso-occlusive devices include mechanical vaso-occlusive devices. Examples of such devices are helically wound coils, ribbons and braids. Various shaped coils have been described.
  • U.S. Patent No. 5,624,461 to Mariant describes a three-dimensional in-filling vaso-occlusive coil.
  • U.S. Patent No. 5,639,277 to Mariant et al. describe embolic coils having twisted helical shapes and
  • U.S. Patent No. 5,649,949 to Wallace et al. describes variable cross-section conical vaso-occlusive coils. A random shape is described, as well.
  • vaso-occlusive coils have also been treated with variety of substances.
  • U.S. Patent No. 4,994,069, to Ritchart et al. describes a vaso-occlusive coil that assumes a linear helical configuration when stretched and a folded, convoluted configuration when relaxed. The stretched condition is used in placing the coil at the desired site (by its passage through the catheter) and the coil assumes a relaxed configuration — which is better suited to occlude the vessel — once the device is so placed.
  • Ritchart et al. describes a variety of shapes.
  • the secondary shapes of the disclosed coils include "flower" shapes and double vortices.
  • the coils may be coated with agarose, collagen, or sugar.
  • U.S. Patent No. 5,669,931 to Kupiecki discloses coils that may be filed or coated with thrombotic or medicinal material.
  • U.S. Patent No. 5,749,894 to Engleson discloses an aneurysm closure method which involves a reformable polymer.
  • U.S. Patent No. 5,536,274 to Neuss shows a spiral implant which may assume a variety of secondary shapes. Some complex shapes can be formed by interconnecting two or more of the spiral-shaped implants. To promote blood coagulation, the implants may be coated with metal particles, silicone, PTFE, rubber latexes, or polymers.
  • vaso-occlusive precursor comprising a biodegradable polymer and at least one bioactive material nor the resulting biodegradable, bioactive polymeric vaso-occlusion produced in situ from the inventive precursor composition.
  • this invention involves a polymeric mixture or occlusive precursor comprising a dissolved or reactable biodegradable polymer and at least one bioactive material in a biologically tolerated solvent-containing solution.
  • the polymeric mixture or occlusive precursor either precipitates on contact with water or water-containing liquids such as blood or reacts in the body to form an inventive, bioactive occlusive mass.
  • the solvent is a solvent such as ethanol because dilute ethanol has only minor toxic or harmful effects to the human body when compared to other organic solvents.
  • the present invention further preferably includes a polymeric precursor or resulting composition containing an x-ray contrast agent.
  • the composition preferably contains as much x-ray contrast agent as possible so that the injection of the inventive composition to the selected site in the body through a long catheter is visible under x-ray fluorometry and thus the injection is controllable.
  • the invention includes a procedure for introducing both the inventive and related solutions into the human body to form the resulting inventive embolic occlusion masses.
  • the invention includes a procedure for introduction of the inventive polymeric mixture or occlusive precursor into or with a mechanical occlusive device such as a coil or braid.
  • This invention includes a composition of matter which may be considered an occlusive agent precursor and the resulting occlusive material.
  • the invention may be used to occlude selected sites within the body.
  • the precursor composition comprises a mixture or solution of : a.) at least one polymer-forming or dissolved polymeric biodegradable material, b.) at least one biologically active material, preferably a medicine or angiogenic material, and c.) a pharmaceutically acceptable carrier solvent.
  • the carrier solvent is selected so that it dissolves the polymer-forming or dissolved polymeric biodegradable material and the one biologically active materials, is acceptable for introduction into the human body with a minimum of side effects, and upon contact with blood or other body fluids either allows the dissolved polymeric biodegradable material to precipitate from solution to form inventive occlusive aggregates of the polymer or permits the polymer-forming material to form a mass.
  • inventive compositions may also contain a dissolved or suspended radio-opacif ⁇ er.
  • Preferred polymers are biodegradable and those that are sufficiently hydrophobic to balance an amount of hydrophilicity on the polymer chain such that the polymer is dissolved in the precursor composition but precipitates from the composition when the precursor composition is diluted by, e.g., blood or saline solutions.
  • Hydrophilicity can be increased via the presence of, e.g., alcoholic groups in the chain. If the hydrophilicity of the polymer is increased too far, however, and too many alcoholic groups are introduced, the polymer itself becomes soluble in blood and thus does not effectively function as an embolic material. Conversely, if the hydrophobicity of the polymer is not controlled, the polymer is not sufficiently soluble in solvents which are both miscible in blood and safe for use in the human body.
  • Optimum polymers which have both the appropriate solubility and the biodegradability include biodegradable polyesters such as polyglycolic acid, polylactic acid, polycaprolactone, and their copolymers as well as polyhydroxybutyrate and polyhydroxyvalerate and their copolymers as well as copolymers with trimethylene and the family of polyemhydrides.
  • biodegradable polyesters such as polyglycolic acid, polylactic acid, polycaprolactone, and their copolymers as well as polyhydroxybutyrate and polyhydroxyvalerate and their copolymers as well as copolymers with trimethylene and the family of polyemhydrides.
  • Other polymers which are generally suitable are those polymers used to form dissolvable sutures for the human body.
  • bioactive materials which increase cell attachment and/or thrombogenicity include both natural and synthetic compounds, e.g., collagen, fibrinogen, vitronectin, other plasma proteins, growth factors (e.g., vascular endothelial growth factor, "VEGF"), synthetic peptides of these and other proteins having attached RGD (arginine- glycine-aspartic acid) residues, generally at one or both termini, or other cell adhesion peptides, i.e., GRGDY, oligonucleotides, full or partial DNA constructs, natural or synthetic phospholipids, or polymers with phosphorylcholine functionality.
  • natural and synthetic compounds e.g., collagen, fibrinogen, vitronectin, other plasma proteins, growth factors (e.g., vascular endothelial growth factor, "VEGF”), synthetic peptides of these and other proteins having attached RGD (arginine- glycine-aspartic acid) residues, generally at one or both termini,
  • polynucleotide sequences encoding peptides may also be used.
  • Other components having a specific role may be included, e.g., genes, growth factors, biomolecules, peptides, oligonucleotides, members of the integrin family, RGD-containing sequences, oligopeptides, e.g., fibronectin, laminin, bitronectin, hyaluronic acid, silk-elastin, elastin, fibrinogen, and other basement membrane proteins with bioactive agents.
  • bioactive materials which may be used in the present invention include, for example, pharmaceutically active compounds, proteins, oligonucleotides, ribozymes, anti- sense genes, DNA compacting agents, gene/vector systems (i.e., anything that allows for the uptake and expression of nucleic acids), nucleic acids (including, for example, naked DNA, cDNA, RNA, DNA, cDNA or RNA in a non-infectious vector or in a viral vector which may have attached peptide targeting sequences; antisense nucleic acid (RNA or DNA); and DNA chimeras which include gene sequences and encoding for ferry proteins such as membrane translocating sequences ("MTS") and herpes simplex virus- 1 (“VP22”)), and viral, liposomes and cationic polymers that are selected from a number of types depending on the desired application, including retrovirus, adenovirus, adeno-associated virus, herpes simplex virus, and the like.
  • MTS membrane translocating sequences
  • VP22
  • biologically active solutes include anti-thrombogenic agents such as heparin, heparin derivatives, urokinase, PPACK (dextrophenylalanine proline arginine chloromethylketone), rapamycin, probucol, and verapimil; angiogenic and anti-angiogenic agents; anti-proliferative agents such as enoxaprin, angiopeptin, or monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid; anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine; antineoplastic/antiproliferative/anti-mitotic agents such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin
  • Polynucleotide sequences useful in practice of the invention include DNA or RNA sequences having a therapeutic effect after being taken up by a cell.
  • therapeutic polynucleotides include anti-sense DNA and RNA; DNA coding for an anti- sense RNA; or DNA coding for tRNA or rRNA to replace defective or deficient endogenous molecules.
  • the polynucleotides of the invention can also code for therapeutic polypeptides.
  • a polypeptide is understood to be any translation production of a polynucleotide regardless of size, and whether glycosylated or not.
  • Therapeutic polypeptides include as a primary example, those polypeptides that can compensate for defective or deficient species in an animal, or those that act through toxic effects to limit or remove harmful cells from the body.
  • the polypeptides or proteins that can be incorporated into the polymer composition, or whose DNA can be incorporated include without limitation, proteins competent to induce angiogenesis, including factors such as, without limitation, acidic and basic fibroblast growth factors, vascular endothelial growth factor (including VEGF-2, VEGF-3, VEGF-A, VEGF-B, VEGF-C) hif-1 and other molecules competent to induce an upstream or downstream effect of an angiogenic factor; epidermal growth factor, transforming growth factor ⁇ and ⁇ , platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor ⁇ , hepatocyte growth factor and insulin like growth factor; growth factors; cell cycle inhibitors including CDK inhibitors; thymidine kinase ("TK”) and other agents useful
  • MCP-1 monocyte chemoattractant protein
  • BMP's the family of bone morphogenic proteins
  • the known proteins include BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Vgr-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-1 1, BMP-12, BMP-13, BMP-14, BMP-15, and BMP-16.
  • BMP's are any of BMP-2,
  • BMP-3, BMP-4, BMP-5, BMP-6 and BMP-7 These dimeric proteins can be provided as homodimers, heterodimers, or combinations thereof, alone or together with other molecules.
  • molecules capable of inducing an upstream or downstream effect of a BMP can be provided.
  • Such molecules include any of the "hedgehog" proteins, or the DNA ' s encoding them.
  • the inventive composition has recombinant nucleic acid incorporated therein, wherein the recombinant nucleic acid comprises a viral vector having linked thereto an exogenous nucleic acid sequence.
  • Exogenous nucleic acid sequence is used herein to mean a sequence of nucleic acids that is exogenous to the virus from which the vector is derived.
  • the concentration of the viral vector preferably an adenoviral vector, is at least about 10 plaque forming units ("p.f.u.”), preferably at least about 10 11 p.f.u.
  • the concentration of the viral vector is limited by the concentration that results in an undesirable immune response from a patient.
  • the bioactive agents may further contain additional materials which have one or more functions, including, but not limited to, providing a therapeutic for local or blood borne delivery, or enhancing thrombosis, coagulation, or platelet activity.
  • An appropriate polymer is dissolved in a suitable solvent for use as an occludant precursor.
  • a suitable solvent for use as an occludant precursor.
  • Appropriate solvents are biologically tolerated or pharmaceutically acceptable in nature and are typically polar, substantially non-toxic, and water miscible.
  • suitable alcohols, ethers, amides, and glycols and their mixtures with each other or with water will be apparent to the worker of ordinary skill in this art.
  • the solvent or solvent system must be able to completely dissolve the chosen polymer and the biologically active agent and then upon introduction of that solution to a mammalian site containing an aqueous medium (naturally occurring or artificially introduced) allow the dissolved polymer to fall out of solution and form an agglomerate.
  • an especially desirable solvent system is a mixture of ethanol and water.
  • the catheters through which these compositions are placed must be quite small.
  • the viscosity of the inventive solution should be minimized, consistent with the other requirements noted herein.
  • the viscosity of a polymer solution is very sensitive to polymer molecular weight (MW W ), particularly at high polymer concentration, the MW W of the polymer should typically be less than about 500,000. However, when the MW decreases, the polymer becomes increasingly soluble in water. Therefore, it is desirable for the polymer to have a MW at least about than 10,000. The desired range is 10,000 to 500,000. The preferable
  • MW is in the range of 50,000-100,000.
  • the concentration of polymer also typically affects both the viscosity of the solution as well as the precipitation behavior of the polymer. Principally because high polymer concentration, polymer solutions exhibit high viscosity and hence are quite unwieldy, lower concentrations, e.g., less than 30% depending upon the chosen polymer, are preferred for immobilization. If the polymer concentration is lower, the polymer occlusive mass may fragment into small pieces when introduced into the bloodstream due to high stress from the blood flow. There is an increased chance for the precipitated polymer to pass the malformation site and to end up in the lungs. About 5-50% polymer solutions are suitable for embolization. That is to say that "weight % polymer" is calculated based on the overall solution content (solvent, water, diluents, radio-opacifiers, etc.).
  • a small amount of a commercial buffer (pH 7) may be desirable.
  • Aqueous ethanolic solutions having higher concentrations of ethanol and the chosen polymers are able to dissolve higher loads of radio-opacifiers such as metrizamide (see, US Pat. No. 3,701,771) or iopromide (see, US Pat No. 4,364,921).
  • Metrizamide is sold in a dilute form as "Amipaque” by Winthrop-Breon Laboratories, a division of Sterling Drug Inc.
  • Iopromide is often sold in a dilute form under the tradename "Ultravist”.
  • radio-opacity may be enhanced by incorporating insoluble agents such as metal powders and salts of radio-opaque metals.
  • the inventive precursor is introduced into the body in the following way.
  • a catheter is introduced via usual procedures to a chosen site in a mammalian body.
  • the site may be, e.g., a Fallopian tube, a ureteral or bile duct, a vascular site, etc.
  • the bolus of precursor material is then introduced into the catheter and injected into the chosen site.
  • the precursor should be introduced slowly so to form an aggregate near the catheter distal tip. More than one injection of precursor is possible using this technique. Once the mass is formed, the catheter is removed.
  • the device is a helically wound coil often wound into a secondary shape of some type.
  • Such devices are often made of a radio-opaque, biocompatible material such as a metal or a polymer.
  • Suitable metals may be selected from gold, rhenium, platinum, palladium, rhodium, ruthenium, various stainless steels, tungsten, and alloys thereof.
  • the preferred alloy is one comprising upwards of 90% platinum and at least a portion of the remainder, tungsten.
  • This alloy exhibits excellent biocompatibility and yet has sufficient strength and ductility to be wound into coils of primary and secondary shape and will retain those shapes upon placement of the vaso-occlusive device in the human body.
  • the diameter of the wire typically making up the coils is often in a range of 0.005 and 0.050 inches, preferably between about .001 and about .003 inches in diameter.
  • the mechanical occlusive devices are associated with some amount of a polymeric material, which may be comprised of a wide variety of materials.
  • Synthetic and natural polymers such as polyurethanes (including copolymers with soft segments containing esters, ethers and carbonates), ethers, acrylates (including cyanoacrylates), olefins (including polymers and copolymers of ethylene, propylene, butenes, butadiene, styrene, and thermoplastic olefin elastomers), polydimethyl siloxane-based polymers, polyethyleneterephthalate, cross-linked polymers, non-cross linked polymers, rayon, cellulose, cellulose derivatives such nitrocellulose, natural rubbers, polyesters such as lactides, glycolides, caprolactones and their copolymers and acid derivatives, hydroxybutyrate and polyhydroxyvalerate and their copolymers, polyether esters such as polydioxinone, anhydrides such as
  • the polymer of our inventive composition precipitates as the solvent mixes with blood, a polymer solution injected through a catheter could precipitate in the catheter. In such an event, the inventive polymer solution likely would not reach the treatment site. Thus, it is highly desirable to separate the inventive polymer solution from the blood during the period of its delivery through the catheter. A plug of a "barrier solvent" is suitable for such separation. Ideally, the barrier solvent is miscible neither with blood nor with the polymer solution. However, many such immiscible solvents would be expected to be toxic to the body.
  • a less effective but nonetheless suitable solvent system e.g., a partially miscible solvent system
  • a less effective but nonetheless suitable solvent system e.g., a partially miscible solvent system
  • a 20-30% aqueous ethanol solution is effective as such a barrier.
  • those devices should be first introduced to the chosen site using the procedure outlined below. This procedure may be used in treating a variety of maladies. For instance, in treatment of an aneurysm, the aneurysm itself may be filled with the mechanical devices prior to introducing the inventive composition. Shortly after the mechanical devices and the inventive composition are placed within the aneurysm, an emboli begins to form and, at some later time, is at least partially replaced by neovascularized collagenous material formed around the vaso- occlusive devices.
  • a selected site is reached through the vascular system using a collection of specifically chosen catheters and guide wires. It is clear that should the site be in a remote site, e.g., in the brain, methods of reaching this site are somewhat limited.
  • One widely accepted procedure is found in U.S. Patent No. 4,994,069 to Ritchart, et al. It utilizes a fine endovascular catheter such as is found in U.S. Patent No. 4,739,768, to Engelson.
  • a large catheter is introduced through an entry site in the vasculature. Typically, this would be through a femoral artery in the groin.
  • a guiding catheter is then used to provide a safe passageway from the entry site to a region near the site to be treated. For instance, in treating a site in the human brain, a guiding catheter would be chosen which would extend from the entry site at the femoral artery, up through the large arteries extending to the heart, around the heart through the aortic arch, and downstream through one of the arteries extending from the upper side of the aorta.
  • a guidewire and neurovascular catheter such as that described in the Engelson patent are then placed through the guiding catheter as a unit.
  • the tip of the guidewire reaches the end of the guiding catheter, it is then extended using fluoroscopy, by the physician to the site to be treated using the vaso-occlusive devices of this invention.
  • the guidewire is advanced for a distance and the neurovascular catheter follows. Once both the distal tip of the neurovascular catheter and the guidewire have reached the treatment site, and the distal tip of that catheter is appropriately situated, e.g., within the mouth of an aneurysm to be treated, the guidewire is then withdrawn.
  • the neurovascular catheter then has an open lumen to the outside of the body.
  • the devices of this invention are then pushed through the lumen to the treatment site. They are held in place variously because of their shape, size, or volume.
  • the mechanical or solid vaso-occlusion device may be used as a kit with the inventive polymeric precursor composition. Modifications of the procedure and device described above, and the methods of using them in keeping with this invention will be apparent to those having skill in this mechanical and surgical art. These variations are intended to be within the scope of the claims that follow.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pour former une occlusion anatomique biologique active, généralement à l'intérieur du système vasculaire d'un patient. Plus particulièrement, l'invention porte sur un agent occlusif pouvant être fabriqué à partir d'une composition de précurseur qui contient au moins un composé polymérique biodégradable et au moins d'un agent biologiquement actif. L'agent occlusif peut, en outre, comprendre des radio-opacifiants solides ou dissous et des dispositifs pour occlusion vasculaire connus. L'occlusion qui en résulte, un solide bioactif, encourage la fixation et la croissance de cellules tout en conservant des caractéristiques de traitement, de déploiement et de visualisation favorables.
PCT/US2000/017886 1999-07-12 2000-06-28 Compositions pour occlusion vasculaire a base de liquide Ceased WO2001003666A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU60580/00A AU6058000A (en) 1999-07-12 2000-06-28 Liquid based vaso-occlusive compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35176999A 1999-07-12 1999-07-12
US09/351,769 1999-07-12

Publications (2)

Publication Number Publication Date
WO2001003666A2 true WO2001003666A2 (fr) 2001-01-18
WO2001003666A3 WO2001003666A3 (fr) 2001-07-26

Family

ID=23382300

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/017886 Ceased WO2001003666A2 (fr) 1999-07-12 2000-06-28 Compositions pour occlusion vasculaire a base de liquide

Country Status (3)

Country Link
US (1) US20020058640A1 (fr)
AU (1) AU6058000A (fr)
WO (1) WO2001003666A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089679A1 (fr) * 2001-05-04 2002-11-14 Concentric Medical Dispositif vaso-occlusif a base d'hydrogel
WO2002089863A1 (fr) * 2001-05-04 2002-11-14 Concentric Medical Dispositif pour occlusion vasculaire en polymere bioactif
WO2002089676A3 (fr) * 2001-05-04 2003-02-27 Concentric Medical Dispositif pour occlusion vasculaire a filament hydrogel

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1051116T3 (da) * 1998-12-01 2009-02-02 Univ Washington Emboliseringsanordning
US7294123B2 (en) * 2003-12-17 2007-11-13 Corris Neurovascular, Inc. Activatable bioactive vascular occlusive device and method of use
US8431145B2 (en) * 2004-03-19 2013-04-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
EP1827527B1 (fr) * 2004-12-06 2016-08-24 Cook Incorporated Dispositifs d'occlusion gonflables, procedes, et systemes
WO2006074060A2 (fr) * 2004-12-30 2006-07-13 Cook Incorporated Dispositifs d'occlusion a inversion, procedes et systemes
WO2007147127A2 (fr) 2006-06-15 2007-12-21 Cook Incorporated Méthodes, systèmes et appareils pour la délivrance de prothèses endoluminales
EP2187983B1 (fr) * 2007-09-12 2014-04-16 Cook Incorporated Matériaux remodelables améliorés servant à oblitérer des vaisseaux corporels
WO2015164218A1 (fr) * 2014-04-23 2015-10-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Néogenèse endogène de cellules bêta

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE392100B (sv) * 1969-06-27 1977-03-14 Nyegaard & Co As Trijodbensoylaminer till anvendning sasom rontgenkontrastmedel eller for separation av biologiska material
DE2909439A1 (de) * 1979-03-08 1980-09-18 Schering Ag Neue nichtionische roentgenkontrastmittel
HU184722B (en) * 1980-02-18 1984-10-29 Laszlo Lazar Therapeutically suitable silicone rubber mixture and therapeuticaid
EP0086627B1 (fr) * 1982-02-12 1985-08-28 Unitika Ltd. Produit anti-cancéreux
US4739768B2 (en) * 1986-06-02 1995-10-24 Target Therapeutics Inc Catheter for guide-wire tracking
US4795741A (en) * 1987-05-06 1989-01-03 Biomatrix, Inc. Compositions for therapeutic percutaneous embolization and the use thereof
US5041090A (en) * 1988-01-12 1991-08-20 Scheglov Viktor I Occluding device
US5749915A (en) * 1988-08-24 1998-05-12 Focal, Inc. Polymeric endoluminal paving process
US4994069A (en) * 1988-11-02 1991-02-19 Target Therapeutics Vaso-occlusion coil and method
US5122136A (en) * 1990-03-13 1992-06-16 The Regents Of The University Of California Endovascular electrolytically detachable guidewire tip for the electroformation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas
US5354295A (en) * 1990-03-13 1994-10-11 Target Therapeutics, Inc. In an endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas
ATE130517T1 (de) * 1990-08-08 1995-12-15 Takeda Chemical Industries Ltd Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.
DE4104702C2 (de) * 1991-02-15 1996-01-18 Malte Neuss Implantate für Organwege in Wendelform
US5328690A (en) * 1991-02-21 1994-07-12 University Of South Alabama Polyamino acid dispersants
US5310407A (en) * 1991-06-17 1994-05-10 Datascope Investment Corp. Laparoscopic hemostat delivery system and method for using said system
DK0617594T3 (da) * 1991-12-12 1998-02-02 Target Therapeutics Inc Adskillelig udstøderkarokklusionsspiralkonstruktion med sammenlåsningskobling
US5234437A (en) * 1991-12-12 1993-08-10 Target Therapeutics, Inc. Detachable pusher-vasoocclusion coil assembly with threaded coupling
US5261916A (en) * 1991-12-12 1993-11-16 Target Therapeutics Detachable pusher-vasoocclusive coil assembly with interlocking ball and keyway coupling
US5403278A (en) * 1992-04-15 1995-04-04 Datascope Investment Corp. Device and method for treating hematomas and false aneurysms
US5250071A (en) * 1992-09-22 1993-10-05 Target Therapeutics, Inc. Detachable embolic coil assembly using interlocking clasps and method of use
US5690666A (en) * 1992-11-18 1997-11-25 Target Therapeutics, Inc. Ultrasoft embolism coils and process for using them
US5443454A (en) * 1992-12-09 1995-08-22 Terumo Kabushiki Kaisha Catheter for embolectomy
US5537338A (en) * 1993-11-24 1996-07-16 Intel Corporation Process and apparatus for bitwise tracking in a byte-based computer system
US5795331A (en) * 1994-01-24 1998-08-18 Micro Therapeutics, Inc. Balloon catheter for occluding aneurysms of branch vessels
US5580588A (en) * 1994-04-14 1996-12-03 Eastman Kodak Company Apparatus for decurling a strip of photosensitive material
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
WO1996021427A1 (fr) * 1995-01-09 1996-07-18 Atrix Laboratories, Inc. Systeme d'administration d'un polymere liquide
US5614204A (en) * 1995-01-23 1997-03-25 The Regents Of The University Of California Angiographic vascular occlusion agents and a method for hemostatic occlusion
US5649959A (en) * 1995-02-10 1997-07-22 Sherwood Medical Company Assembly for sealing a puncture in a vessel
NO961280L (no) * 1995-03-30 1996-10-01 Target Therapeutics Inc Væskespoler med sekundær form
US5639277A (en) * 1995-04-28 1997-06-17 Target Therapeutics, Inc. Embolic coils with offset helical and twisted helical shapes
US5624461A (en) * 1995-06-06 1997-04-29 Target Therapeutics, Inc. Three dimensional in-filling vaso-occlusive coils
US5785679A (en) * 1995-07-19 1998-07-28 Endotex Interventional Systems, Inc. Methods and apparatus for treating aneurysms and arterio-venous fistulas
US5667767A (en) * 1995-07-27 1997-09-16 Micro Therapeutics, Inc. Compositions for use in embolizing blood vessels
GB9515986D0 (en) * 1995-08-04 1995-10-04 Racal Health & Safety Ltd Uni-directional fluid valve
US5749894A (en) * 1996-01-18 1998-05-12 Target Therapeutics, Inc. Aneurysm closure method
US5702361A (en) * 1996-01-31 1997-12-30 Micro Therapeutics, Inc. Method for embolizing blood vessels
US5649949A (en) * 1996-03-14 1997-07-22 Target Therapeutics, Inc. Variable cross-section conical vasoocclusive coils
AU2745497A (en) * 1996-05-31 1998-01-05 Micro Therapeutics, Inc. Compositions for use in embolizing blood vessels
US5830178A (en) * 1996-10-11 1998-11-03 Micro Therapeutics, Inc. Methods for embolizing vascular sites with an emboilizing composition comprising dimethylsulfoxide
US5695480A (en) * 1996-07-29 1997-12-09 Micro Therapeutics, Inc. Embolizing compositions
US5823198A (en) * 1996-07-31 1998-10-20 Micro Therapeutics, Inc. Method and apparatus for intravasculer embolization
US5925683A (en) * 1996-10-17 1999-07-20 Target Therapeutics, Inc. Liquid embolic agents
US5776097A (en) * 1996-12-19 1998-07-07 University Of California At Los Angeles Method and device for treating intracranial vascular aneurysms
ATE203157T1 (de) * 1996-12-20 2001-08-15 Alza Corp Injizierbare depotgelzubereitung und herstellungsverfahren
US5891192A (en) * 1997-05-22 1999-04-06 The Regents Of The University Of California Ion-implanted protein-coated intralumenal implants
US6146373A (en) * 1997-10-17 2000-11-14 Micro Therapeutics, Inc. Catheter system and method for injection of a liquid embolic composition and a solidification agent
US6015541A (en) * 1997-11-03 2000-01-18 Micro Therapeutics, Inc. Radioactive embolizing compositions
US5935145A (en) * 1998-02-13 1999-08-10 Target Therapeutics, Inc. Vaso-occlusive device with attached polymeric materials
US6818018B1 (en) * 1998-08-14 2004-11-16 Incept Llc In situ polymerizable hydrogels
JP5148030B2 (ja) * 1999-05-21 2013-02-20 タイコ ヘルスケア グループ リミテッド パートナーシップ 新規の高粘度塞栓形成組成物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089679A1 (fr) * 2001-05-04 2002-11-14 Concentric Medical Dispositif vaso-occlusif a base d'hydrogel
WO2002089863A1 (fr) * 2001-05-04 2002-11-14 Concentric Medical Dispositif pour occlusion vasculaire en polymere bioactif
WO2002089676A3 (fr) * 2001-05-04 2003-02-27 Concentric Medical Dispositif pour occlusion vasculaire a filament hydrogel

Also Published As

Publication number Publication date
WO2001003666A3 (fr) 2001-07-26
US20020058640A1 (en) 2002-05-16
AU6058000A (en) 2001-01-30

Similar Documents

Publication Publication Date Title
EP1372493B1 (fr) Bobine d'occlusion bioactive
EP1416862B1 (fr) Spirale d'occlusion bioactive
US6663607B2 (en) Bioactive aneurysm closure device assembly and kit
US8016852B2 (en) Bioactive components for incorporation with vaso-occlusive members
JP4211888B2 (ja) その場（インサイチュ）で強化できる塞栓装置
US6423085B1 (en) Biodegradable polymer coils for intraluminal implants
US20020082620A1 (en) Bioactive materials for aneurysm repair
JP2006506171A (ja) ナノファイバでできた塞栓装置
JP2010012282A (ja) 吸収性移植可能血管閉塞部材
US6616591B1 (en) Radioactive compositions and methods of use thereof
JP4443229B2 (ja) 動脈瘤修復のための方法
US20020058640A1 (en) Liquid based vaso-occlusive compositions
US20090163945A1 (en) Polymeric slotted tube coils
Klisch et al. Combined stent implantation and embolization with liquid 2-polyhydroxyethyl methacrylate for treatment of experimental canine wide-necked aneurysms

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP